• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

相似文献

1
Characterization of iduronate sulphatase mutants affecting N-glycosylation sites and the cysteine-84 residue.影响N-糖基化位点和半胱氨酸-84残基的艾杜糖醛酸硫酸酯酶突变体的特征分析
Biochem J. 1997 Aug 15;326 ( Pt 1)(Pt 1):243-7. doi: 10.1042/bj3260243.
2
COS cell expression studies of P86L, P86R, P480L and P480Q Hunter's disease-causing mutations.
Biochim Biophys Acta. 1998 Mar 5;1406(2):214-8. doi: 10.1016/s0925-4439(97)00096-3.
3
Analysis of normal and mutant iduronate-2-sulphatase conformation.正常和突变型艾杜糖醛酸-2-硫酸酯酶构象分析
Biochem J. 2005 Mar 1;386(Pt 2):395-400. doi: 10.1042/BJ20040739.
4
The effect of four mutations on the expression of iduronate-2-sulfatase in mucopolysaccharidosis type II.四种突变对II型黏多糖贮积症中艾杜糖醛酸-2-硫酸酯酶表达的影响。
Biochim Biophys Acta. 2001 Nov 29;1537(3):233-8. doi: 10.1016/s0925-4439(01)00075-8.
5
Effect of Hunter disease (mucopolysaccharidosis type II) mutations on molecular phenotypes of iduronate-2-sulfatase: enzymatic activity, protein processing and structural analysis.亨特氏病(II型黏多糖贮积症)突变对艾杜糖醛酸-2-硫酸酯酶分子表型的影响:酶活性、蛋白质加工及结构分析
J Inherit Metab Dis. 2006 Dec;29(6):755-61. doi: 10.1007/s10545-006-0440-7. Epub 2006 Nov 7.
6
Expression of five iduronate-2-sulfatase site-directed mutations.
Biochim Biophys Acta. 2000 Jun 15;1501(2-3):71-80. doi: 10.1016/s0925-4439(00)00006-5.
7
Molecular investigations of a novel iduronate-2-sulfatase mutant in a Chinese patient.一名中国患者中新型艾杜糖醛酸-2-硫酸酯酶突变体的分子研究。
Clin Chim Acta. 2008 Jun;392(1-2):8-10. doi: 10.1016/j.cca.2008.02.009. Epub 2008 Apr 8.
8
Molecular basis of iduronate-2-sulphatase gene mutations in patients with mucopolysaccharidosis type II (Hunter syndrome).II型粘多糖贮积症(亨特综合征)患者艾杜糖醛酸-2-硫酸酯酶基因突变的分子基础
J Med Genet. 1999 Jan;36(1):21-7.
9
A novel amino acid modification in sulfatases that is defective in multiple sulfatase deficiency.一种在多种硫酸酯酶缺乏症中存在缺陷的硫酸酯酶中的新型氨基酸修饰。
Cell. 1995 Jul 28;82(2):271-8. doi: 10.1016/0092-8674(95)90314-3.
10
Endoplasmic Reticulum and Lysosomal Quality Control of Four Nonsense Mutants of Iduronate 2-Sulfatase Linked to Hunter's Syndrome.黏多糖贮积症Ⅱ型(Hunter 综合征)相关的艾杜糖-2-硫酸酯酶四个无义突变的内质网和溶酶体质量控制
DNA Cell Biol. 2020 Feb;39(2):226-234. doi: 10.1089/dna.2019.5221. Epub 2020 Jan 2.

引用本文的文献

1
Domain-substituted IGF2 tag modulates targeting of lentiviral gene therapy for Hunter syndrome.
EMBO Mol Med. 2025 Sep 29. doi: 10.1038/s44321-025-00314-3.
2
A novel CRISPR/Cas9-based iduronate-2-sulfatase (IDS) knockout human neuronal cell line reveals earliest pathological changes.一种新型基于 CRISPR/Cas9 的艾杜糖-2-硫酸酯酶 (IDS) 敲除人神经元细胞系揭示了最早的病理变化。
Sci Rep. 2023 Jun 25;13(1):10289. doi: 10.1038/s41598-023-37138-5.
3
Characterization of a HIR-Fab-IDS, Novel Iduronate 2-Sulfatase Fusion Protein for the Treatment of Neuropathic Mucopolysaccharidosis Type II (Hunter Syndrome).新型艾杜糖-2-硫酸酯酶融合蛋白 HIR-Fab-IDS 的鉴定及其用于治疗黏多糖贮积症 II 型(亨特综合征)的研究
BioDrugs. 2023 May;37(3):375-395. doi: 10.1007/s40259-023-00590-w. Epub 2023 Apr 4.
4
A universal GlycoDesign for lysosomal replacement enzymes to improve circulation time and biodistribution.一种用于溶酶体替代酶的通用糖基设计,以改善循环时间和生物分布。
Front Bioeng Biotechnol. 2023 Feb 24;11:1128371. doi: 10.3389/fbioe.2023.1128371. eCollection 2023.
5
Molecular architecture determines brain delivery of a transferrin receptor-targeted lysosomal enzyme.分子结构决定转铁蛋白受体靶向溶酶体酶的脑内递送。
J Exp Med. 2022 Mar 7;219(3). doi: 10.1084/jem.20211057. Epub 2022 Feb 28.
6
Loss of Function of Mutant IDS Due to Endoplasmic Reticulum-Associated Degradation: New Therapeutic Opportunities for Mucopolysaccharidosis Type II.由于内质网相关降解导致的突变 IDS 功能丧失:黏多糖贮积症 II 型的新治疗机会。
Int J Mol Sci. 2021 Nov 12;22(22):12227. doi: 10.3390/ijms222212227.
7
Ancestral lysosomal enzymes with increased activity harbor therapeutic potential for treatment of Hunter syndrome.活性增强的祖先溶酶体酶具有治疗亨特综合征的治疗潜力。
iScience. 2021 Feb 6;24(3):102154. doi: 10.1016/j.isci.2021.102154. eCollection 2021 Mar 19.
8
Comparative study of idursulfase beta and idursulfase in vitro and in vivo.艾度硫酸酯酶β与艾度硫酸酯酶的体内外比较研究
J Hum Genet. 2017 Feb;62(2):167-174. doi: 10.1038/jhg.2016.133. Epub 2016 Nov 10.
9
Deep Genotyping of the IDS Gene in Colombian Patients with Hunter Syndrome.哥伦比亚亨特综合征患者IDS基因的深度基因分型
JIMD Rep. 2015;19:101-9. doi: 10.1007/8904_2014_376. Epub 2015 Feb 15.
10
A biochemical and physicochemical comparison of two recombinant enzymes used for enzyme replacement therapies of hunter syndrome.用于亨特综合征酶替代疗法的两种重组酶的生化和物理化学比较。
Glycoconj J. 2014 May;31(4):309-15. doi: 10.1007/s10719-014-9523-0. Epub 2014 Apr 30.

本文引用的文献

1
IDS transfer from overexpressing cells to IDS-deficient cells.
Exp Cell Res. 1997 Feb 1;230(2):362-7. doi: 10.1006/excr.1996.3435.
2
The role of glycosylation and phosphorylation in the expression of active human beta-glucuronidase.糖基化和磷酸化在活性人β-葡萄糖醛酸酶表达中的作用。
J Biol Chem. 1993 Jun 5;268(16):12193-8.
3
Human lysosomal alpha-glucosidase: functional characterization of the glycosylation sites.人溶酶体α-葡萄糖苷酶:糖基化位点的功能特性
Biochem J. 1993 Feb 1;289 ( Pt 3)(Pt 3):681-6. doi: 10.1042/bj2890681.
4
Hunter syndrome: gene deletions and rearrangements.亨特综合征:基因缺失与重排
Hum Mutat. 1993;2(2):138-40. doi: 10.1002/humu.1380020214.
5
Intracellular sorting of aspartylglucosaminidase: the role of N-linked oligosaccharides and evidence of Man-6-P-independent lysosomal targeting.天冬氨酰葡糖胺酶的细胞内分选:N-连接寡糖的作用及不依赖甘露糖-6-磷酸的溶酶体靶向证据
DNA Cell Biol. 1995 Apr;14(4):305-12. doi: 10.1089/dna.1995.14.305.
6
A novel amino acid modification in sulfatases that is defective in multiple sulfatase deficiency.一种在多种硫酸酯酶缺乏症中存在缺陷的硫酸酯酶中的新型氨基酸修饰。
Cell. 1995 Jul 28;82(2):271-8. doi: 10.1016/0092-8674(95)90314-3.
7
Processing of iduronate 2-sulphatase in human fibroblasts.人成纤维细胞中艾杜糖醛酸2-硫酸酯酶的加工
Biochem J. 1995 Jul 15;309 ( Pt 2)(Pt 2):425-30. doi: 10.1042/bj3090425.
8
Biochemical variability of arylsulphatases -A, -B and -C in cultured fibroblasts from patients with multiple sulphatase deficiency.多种硫酸酯酶缺乏症患者培养成纤维细胞中芳基硫酸酯酶A、B和C的生化变异性
J Inherit Metab Dis. 1983;6(4):167-72. doi: 10.1007/BF02310875.
9
Analysis of the glycosylation and phosphorylation of the lysosomal enzyme, beta-hexosaminidase B, by site-directed mutagenesis.
J Biol Chem. 1989 May 5;264(13):7692-7.
10
Directional antisense and sense cDNA cloning using Epstein-Barr virus episomal expression vectors.使用爱泼斯坦-巴尔病毒附加型表达载体进行定向反义及正义cDNA克隆。
Gene. 1989 Sep 30;81(2):285-94. doi: 10.1016/0378-1119(89)90189-3.

影响N-糖基化位点和半胱氨酸-84残基的艾杜糖醛酸硫酸酯酶突变体的特征分析

Characterization of iduronate sulphatase mutants affecting N-glycosylation sites and the cysteine-84 residue.

作者信息

Millat G, Froissart R, Maire I, Bozon D

机构信息

Centre d'études des Maladies Métaboliques, Hôpital Debrousse, Lyon, France.

出版信息

Biochem J. 1997 Aug 15;326 ( Pt 1)(Pt 1):243-7. doi: 10.1042/bj3260243.

DOI:10.1042/bj3260243
PMID:9337875
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC1218661/
Abstract

Iduronate sulphatase (IDS) is responsible for mucopolysaccharidosis type II, a rare recessive X-linked lysosomal storage disease. The aim of this work was to evaluate the functional importance of each N-glycosylation site, and of the cysteine-84 residue. IDS mutant cDNAs, lacking one of the eight potential N-glycosylation sites, were expressed in COS cells. Although each of the potential sites was used, none of the eight glycosylation sites appeared to be essential for lysosomal targeting. Another important sulphatase co- or post-translational modification for generating catalytic activity involves the conversion of a cysteine residue surrounded by a conserved sequence C-X-P-S-R into a 2-amino-3-oxopropionic acid residue [Schmidt, Selmer, Ingendoh and von Figura (1995) Cell 82, 271-278]. This conserved cysteine, located at amino acid position 84 in IDS, was replaced either by an alanine (C84A) or by a threonine (C84T) using site-directed mutagenesis. C84A and C84T mutant cDNAs were expressed either in COS cells or in human lymphoblastoid cells deleted for the IDS gene. C84A had a drastic effect both for IDS processing and for catalytic activity. The C84T mutation produced a small amount of mature forms but also abolished enzyme activity, confirming that the cysteine residue at position 84 is required for IDS activity.

摘要

艾杜糖醛酸硫酸酯酶(IDS)与II型粘多糖贮积症有关,这是一种罕见的X连锁隐性溶酶体贮积病。本研究的目的是评估每个N-糖基化位点以及半胱氨酸84残基的功能重要性。缺乏八个潜在N-糖基化位点之一的IDS突变cDNA在COS细胞中表达。尽管每个潜在位点都被利用,但八个糖基化位点似乎都不是溶酶体靶向所必需的。另一种对产生催化活性很重要的硫酸酯酶共翻译或翻译后修饰涉及将被保守序列C-X-P-S-R包围的半胱氨酸残基转化为2-氨基-3-氧代丙酸残基[施密特、塞尔默、英根多和冯·菲古拉(1995年)《细胞》82卷,271 - 278页]。位于IDS氨基酸位置84的这个保守半胱氨酸,通过定点诱变被丙氨酸(C84A)或苏氨酸(C84T)取代。C84A和C84T突变cDNA在COS细胞或缺失IDS基因的人淋巴母细胞中表达。C84A对IDS加工和催化活性都有显著影响。C84T突变产生了少量成熟形式,但也消除了酶活性,证实了84位的半胱氨酸残基是IDS活性所必需的。